Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general meeting (the “Meeting”) held on June 7, 2021.
Detailed results of the vote by proxy for the election of directors are provided below:
|
Nominee |
Votes For (%) |
Votes Withheld (%) |
||||||
|
George M. Milne |
80.91 |
|
|
|
19.09 |
|||
|
Peter Greenleaf |
92.18 |
|
|
|
7.82 |
|||
|
David R.W. Jayne |
93.00 |
|
|
|
7.00 |
|||
|
Joseph P. Hagan |
87.15 |
|
|
|
12.85 |
|||
|
Daniel G. Billen |
95.64 |
|
|
|
4.36 |
|||
|
R. Hector MacKay-Dunn |
93.27 |
|
|
|
6.73 |
|||
|
Jill Leversage |
95.05 |
|
|
|
4.95 |
|||
|
Timothy P. Walbert |
89.56 |
|
|
|
10.44 |
In addition, following final tallies of votes, all other matters voted on at the Meeting were also approved. Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005782/en/
Aurinia Pharmaceuticals Inc. Aktie
Noch kein Trend erkennbar: Aurinia Pharmaceuticals Inc. mit nur einigen Buy- und Sell-Einschätzungen.
Trotz eines Kursziels von 10 € für Aurinia Pharmaceuticals Inc., das über 5.68 € liegt, zeigt sich ein Potenzial von 75.99%.
